Brokerages Set GSK plc (LON:GSK) PT at GBX 1,805.83

Shares of GSK plc (LON:GSK) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is GBX 1,805.83 ($22.48).

Several analysts have recently commented on the stock. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank reduced their price target on shares of GSK from GBX 1,820 ($22.65) to GBX 1,600 ($19.92) and set a “buy” rating for the company in a research report on Friday, November 29th.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,434 ($17.85) on Friday. The company has a market cap of £58.51 billion, a price-to-earnings ratio of 1,269.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 52 week low of GBX 1,282.50 ($15.96) and a 52 week high of GBX 1,823.50 ($22.70). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The firm has a 50 day moving average of GBX 1,363.57 and a 200-day moving average of GBX 1,455.91.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 12.83% and a return on equity of 33.30%. On average, equities analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Activity at GSK

In related news, insider Jonathan Symonds acquired 1,500 shares of the company’s stock in a transaction on Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.37) per share, for a total transaction of £19,725 ($24,551.90). Also, insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.09), for a total value of £1,753,088.09 ($2,182,086.25). 1.61% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.